Enzon Pharmaceuticals Inc (ENZN) financial statements (2022 and earlier)

Company profile

Business Address 20 COMMERCE DRIVE, SUITE 135
CRANFORD, NJ 07016
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments47,64148,1425,4466,5007,4787,63911,672
Cash and cash equivalents47,64148,1425,4466,5007,4787,63911,672
Receivables  4859703,500  
Other current assets8559627094270107
Other undisclosed current assets 31 7,000(3,500)  
Total current assets:47,72648,2325,99314,5407,5727,90911,779
Noncurrent Assets
Nontrade receivables  4859701,940  
Deferred tax assets, net  3,36211,111
Total noncurrent assets:  4859701,9403,36211,111
Other undisclosed assets28      
TOTAL ASSETS:47,75448,2326,47815,5109,51211,27122,890
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities403412423517368940295
Accounts payable33130232443922577090
Accrued liabilities721109978143170205
Other undisclosed current liabilities      4,506
Total current liabilities:4034124235173689404,801
Noncurrent Liabilities
Total liabilities:4034124235173689404,801
Stockholders' equity
Stockholders' equity attributable to parent4,8687,3606,05514,9939,14410,33118,089
Common stock742742442442442441441
Additional paid in capital75,98378,00675,69083,64983,64990,28296,914
Accumulated deficit(71,857)(71,388)(70,077)(69,098)(74,947)(80,392)(79,266)
Total stockholders' equity:4,8687,3606,05514,9939,14410,33118,089
Other undisclosed liabilities and equity42,48340,460     
TOTAL LIABILITIES AND EQUITY:47,75448,2326,47815,5109,51211,27122,890

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues701522076,9188,3798,37717,456
Revenue, net8,3798,37717,456
Gross profit:701522076,9188,3798,37717,456
Operating expenses(1,170)(1,357)(1,180)(1,063)(1,371)(1,733)(6,656)
Operating income (loss):(469)(1,305)(973)5,8557,0086,64410,800
Nonoperating income
(Other Nonoperating income)
71     
Income (loss) from continuing operations before income taxes:(462)(1,304)(973)5,8557,0086,64410,800
Income tax expense (benefit)(7)(7)(6)(6)(1,563)(7,770)10,837
Net income (loss) attributable to parent:(469)(1,311)(979)5,8495,445(1,126)21,637
Preferred stock dividends and other adjustments(2,023)(460)     
Net income (loss) available to common stockholders, diluted:(2,492)(1,771)(979)5,8495,445(1,126)21,637

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(469)(1,311)(979)5,8495,445(1,126)21,637
Comprehensive income (loss), net of tax, attributable to parent:(469)(1,311)(979)5,8495,445(1,126)21,637

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: